Business Description
Guard Therapeutics International AB
ISIN : SE0021181559
Compare
Compare
Traded in other countries / regions
GUARD.Sweden5LH0.Germany IPO Date
2013-04-03Description
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.78 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.5 | |||||
| 3-Year EPS without NRI Growth Rate | 2.5 | |||||
| 3-Year FCF Growth Rate | -0.2 | |||||
| 3-Year Book Growth Rate | -29.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.23 | |||||
| 9-Day RSI | 67.84 | |||||
| 14-Day RSI | 67.81 | |||||
| 6-1 Month Momentum % | -43.75 | |||||
| 12-1 Month Momentum % | 175.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.13 | |||||
| Quick Ratio | 5.13 | |||||
| Cash Ratio | 5.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -99.28 | |||||
| ROA % | -82.08 | |||||
| ROIC % | -913.49 | |||||
| ROC (Joel Greenblatt) % | -1030163.64 | |||||
| ROCE % | -97.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.49 | |||||
| Price-to-Tangible-Book | 4.49 | |||||
| EV-to-EBIT | -1.91 | |||||
| EV-to-EBITDA | -1.91 | |||||
| EV-to-FCF | -1.84 | |||||
| Price-to-Net-Current-Asset-Value | 4.49 | |||||
| Price-to-Net-Cash | 4.6 | |||||
| Earnings Yield (Greenblatt) % | -52.42 | |||||
| FCF Yield % | -38.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guard Therapeutics International AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -11.763 | ||
| Beta | 2.15 | ||
| Volatility % | 388.73 | ||
| 14-Day RSI | 67.81 | ||
| 14-Day ATR (kr) | 2.895664 | ||
| 20-Day SMA (kr) | 24.05 | ||
| 12-1 Month Momentum % | 175.86 | ||
| 52-Week Range (kr) | 5.1 - 49.8 | ||
| Shares Outstanding (Mil) | 10.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guard Therapeutics International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guard Therapeutics International AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guard Therapeutics International AB Frequently Asked Questions
What is Guard Therapeutics International AB(OSTO:GUARD)'s stock price today?
The current price of OSTO:GUARD is kr29.80. The 52 week high of OSTO:GUARD is kr49.80 and 52 week low is kr5.10.
When is next earnings date of Guard Therapeutics International AB(OSTO:GUARD)?
The next earnings date of Guard Therapeutics International AB(OSTO:GUARD) is 2024-05-08.
Does Guard Therapeutics International AB(OSTO:GUARD) pay dividends? If so, how much?
Guard Therapeutics International AB(OSTO:GUARD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers